(P051) Correlative Study of Thyroid DVH and Incidence of Subsequent Thyroid Dysfunction After Head and Neck Radiotherapy

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

In this small cohort of patients, we were able to show increased incidence of thyroid abnormalities after radiotherapy as compared with the normal population.

Stella Ling, MD, Phuong Nguyen, MD, Yi Rong, PhD, Jennifer Sipos, MD; Ohio State University

Materials and Methods: Using departmental databases, we were able to identify 65 patients who had head and neck radiotherapy from January 2008 to December 2009 as part of their overall treatment for head and neck cancer. Three patients were censored because of surgical intrusion on the thyroid gland, leaving us with a study cohort of 62 patients. Treatment planning of all these patients had been done on Pinnacle treatment planning software.

Results: We were able to retrospectively contour in the thyroid glands on these patients and assess the dose-volume histograms (DVHs) of the thyroid gland. In none of the patients was the thyroid gland considered an organ at risk (OAR). Twenty-four patients (38.7%) subsequently developed thyroid abnormalities, either clinical or subclinical, as expressed by changes in thyroid-stimulating hormone (TSH) and free T4 and clinical history. Further, 25% of the women and 42% of the men developed such abnormalities. The median time to developing abnormalities was 7.8 months after starting radiotherapy treatment, and the earliest abnormality was noted at 1.3 months after starting treatment. Ten of the abnormalities were within the first 6 months after starting radiotherapy. The median age of patients who developed thyroid abnormalities was 50 years, and was 57 years for those who did not develop abnormalities (difference not statistically significant). The correlation of thyroid DVH with subsequent abnormality trended toward significance at D50  with P < .117.

Conclusion: In this small cohort of patients, we were able to show increased incidence of thyroid abnormalities after radiotherapy as compared with the normal population. Males and patients less than 55 years of age may be at somewhat higher risk. Thyroid evaluation should be undertaken prior to starting head and neck radiation and again at subsequent follow-ups, even at the 1-month follow-up. Consideration should be given to including the thyroid gland as an OAR, with contouring being done at the time of treatment planning.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Related Content